Takeda Pharmaceutical Company Limited has announced its plan to sell 7 additional long-listed products in Japan to Teva Takeda Yakuhin Ltd. on May 1, 2017, for the selling price of 28.5 billion yen.
Upon the establishment of Teva Takeda Yakuhin in April 2016, Takeda transferred long-listed products including “Blopress (single agent),” “Takepron (single agent)” and “Basen”, to meet the broad needs of patients and medical professionals in Japan.
On May 1, 2017, Takeda will sell the following additional products to Teva Takeda Yakuhin. As of the date of sale, Teva Takeda Yakuhin will be responsible for the information supply activities for these products.
Actos tablets 15/30; Actos OD tablets 15/30; Sonias combination tablets LD/HD; Metact combination tablets LD/HD for the treatment of type 2 diabetes mellitus: Ecard combination tablets LD/HD; Unisia combination tablets LD/HD for hypertension treatment and fixed-dose combination of low dose aspirin & lansoprazole for peptic ulcers.
Revenue of these products in FY2015 amounted to a total of 39.2 billion yen. FY2016 revenue for these products is 24.2 billion yen. In FY2017, Takeda will recognize one-time pre-tax gain of approximately 15 billion yen with the remaining gain deferred over the subsequent 15 years. The gains will be recognized in revenue. The transaction allows Takeda to divest non-core products and free up cash to reinvest in its core therapeutic areas.
“This sale of additional products is in line with visions of both companies; Teva Takeda Yakuhin which promotes business in off-patent drugs, and Takeda which focuses on innovative products, and both companies will further meet the diversified needs of patients and medical professionals in Japan.” said Masato Iwasaki, Ph.D., president of Takeda’s Japan Pharma Business Unit. “As well as supporting the business of Teva Takeda Yakuhin and Teva Takeda Pharma Ltd., Takeda will further reinforce its activities to lead healthcare innovation through supplying innovative new drugs and continuously growing as a leading company in the Japanese pharmaceutical industry.”